N@N

KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"

^{Published on 2013-04-17 20:00:47 - Market Wire}
 

KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013... -- SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ --

[ ]

[ Download image ]

SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: [ KBIO ]) today announced that David Pritchard , President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."

(Logo: [ http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ])

Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.

Breakout Session: Innovations and Opportunities in Vaccines
Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
When:Tuesday, April 23, 2013, 9:00 – 10:15 AM
Where: McCormick Place, Room S402A

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at [ http://www.kalobios.com ].

Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
[ ir@kalobios.com ]

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile: (415) 690-0210
[ Joan@Kureczka-Martin.com ]

SOURCE KaloBios Pharmaceuticals